Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Perspectives on the development of imatinib and the future of cancer research.

Literature DB >> 19812576

Perspectives on the development of imatinib and the future of cancer research.

Brian J Druker¹.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2009 PMID： 19812576 DOI： 10.1038/nm1009-1149

Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440

× No keyword cloud information.

19 in total

1. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B.

Authors: David M Dilts; Alan B Sandler; Matthew Baker; Steven K Cheng; Stephen L George; Kathleen S Karas; Stephen McGuire; Gourija S Menon; Jason Reusch; Debbie Sawyer; Maren Scoggins; Amy Wu; Kai Zhou; Richard L Schilsky
Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544

2. Major response to imatinib mesylate in KIT-mutated melanoma.

Authors: F Stephen Hodi; Philip Friedlander; Christopher L Corless; Michael C Heinrich; Suzanne Mac Rae; Andrea Kruse; Jyothi Jagannathan; Annick D Van den Abbeele; Elsa F Velazquez; George D Demetri; David E Fisher
Journal: J Clin Oncol Date: 2008-04-20 Impact factor: 44.544

Review 3. Enhancing the efficacy of hormonal agents with selected targeted agents.

Authors: Stephen R D Johnston
Journal: Clin Breast Cancer Date: 2009-06 Impact factor: 3.225

4. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors: B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal: N Engl J Med Date: 2001-04-05 Impact factor: 91.245

5. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors: J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal: Science Date: 2004-04-29 Impact factor: 47.728

6. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Authors: Charles D Blanke; George D Demetri; Margaret von Mehren; Michael C Heinrich; Burton Eisenberg; Jonathan A Fletcher; Christopher L Corless; Christopher D M Fletcher; Peter J Roberts; Daniela Heinz; Elisabeth Wehre; Zariana Nikolova; Heikki Joensuu
Journal: J Clin Oncol Date: 2008-02-01 Impact factor: 44.544

7. Commentary: practicing on the tip of an information iceberg? Evidence of underpublication of registered clinical trials in oncology.

Authors: Scott Ramsey; John Scoggins
Journal: Oncologist Date: 2008-09-15

8. An integrated genomic analysis of human glioblastoma multiforme.

Authors: D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal: Science Date: 2008-09-04 Impact factor: 47.728

9. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors: Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal: N Engl J Med Date: 2009-06-24 Impact factor: 91.245

10. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Authors: Jeffrey A Engelman; Liang Chen; Xiaohong Tan; Katherine Crosby; Alexander R Guimaraes; Rabi Upadhyay; Michel Maira; Kate McNamara; Samanthi A Perera; Youngchul Song; Lucian R Chirieac; Ramneet Kaur; Angela Lightbown; Jessica Simendinger; Timothy Li; Robert F Padera; Carlos García-Echeverría; Ralph Weissleder; Umar Mahmood; Lewis C Cantley; Kwok-Kin Wong
Journal: Nat Med Date: 2008-11-30 Impact factor: 53.440

47 in total

10. Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?

Authors: Cyril Benes; Jeff Settleman
Journal: BMC Med Date: 2009-12-14 Impact factor: 8.775

Perspectives on the development of imatinib and the future of cancer research.

1. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B.

2. Major response to imatinib mesylate in KIT-mutated melanoma.

Review 3. Enhancing the efficacy of hormonal agents with selected targeted agents.

4. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

5. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

6. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

7. Commentary: practicing on the tip of an information iceberg? Evidence of underpublication of registered clinical trials in oncology.

8. An integrated genomic analysis of human glioblastoma multiforme.

9. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

10. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

1. Electrospray post-ionization mass spectrometry of electrosurgical aerosols.

2. The evolving role of the pathologist in the management of lung cancer.

Review 3. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements.

4. Identification of novel CK2 inhibitors with a benzofuran scaffold by novel non-radiometric in vitro assays.

5. Personalized medicine: does the molecular suit fit?

6. Personalized cancer medicine: are we there yet?

Review 7. Leukaemia 'firsts' in cancer research and treatment.

8. Comprehensive geriatric assessment in the older cancer patient: coming of age in clinical cancer care.

9. Rethinking screening.

10. Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?